- Obesity increased risk; physical activity lowered risk.
- Data consistent with prior research linking exercise to decreased mortality.
- Research on colon cancer should incorporate heterogeneity of disease.
“We know that exercise and avoiding obesity decrease colorectal cancer risk, but little is known about why,” said Shuji Ogino, M.D., Ph.D., associate professor of pathology at Dana-Farber Cancer Institute and associate professor in the Department of Epidemiology at Harvard School of Public Health in Boston, Mass. “In this study, we used a biomarker named CTNNB1, which is a molecule implicated in cancer and obesity, to divide patients into two groups, CTNNB1-positive and CTNNB1-negative.”
Ogino and colleagues used data from more than 100,000 women from the Nurses’ Health Study and more than 45,000 men in the Health Professionals Study to examine whether there was an association between body mass index (BMI) or exercise activity and colorectal cancer risk according to CTNNB1 expression status.
Among the study population, 2,263 individuals were diagnosed with colorectal cancer during follow-up. Tumor CTNNB1 expression data were available for 861 of these individuals, and 54 percent of these tumors were negative for CTNNB1 and 46 percent positive for the biomarker.
Increasing BMI by a 5.0 kg/m2 increment was associated with a 34 percent higher risk for CTNNB1-negative cancer, but was not associated with CTNNB1-positive cancer. In contrast, increasing physical activity level was associated with a significantly lower risk for CTNNB1-negative cancer. It was not associated with CTNNB1-positive cancer.
“Our results provide additional evidence for a causal role of obesity and a physically inactive lifestyle in a specific molecular subtype of colorectal cancer,” Ogino said. “If physicians are able to identify individuals who are prone to develop CTNNB1-negative cancer, then it would be possible to strongly recommend physical activity.”
In addition, the data indicated that CTNNB1 could be a potential target for chemoprevention and treatment, according to Ogino. He called for more population-based, large-scale databases to facilitate molecular pathological epidemiology research.
“Currently, most population-based studies do not take tumor heterogeneity into consideration, and typically colon cancer is treated as a single disease,” Ogino said. “We need to integrate molecular pathology and epidemiology in education and research to facilitate integrative science and improve public health.”
About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 17,000 attendees. In addition, the AACR publishes eight peer-reviewed scientific journals and a magazine for cancer survivors, patients and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the scientific partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit www.AACR.org.